Hong Kong Pharmaceutical & Chinese Medicine Licensing Guide

1. Dual-Track Statutory Architecture & Licence Number Anatomy (Cap. 138 Western Drugs vs. Cap. 549 Chinese Medicines)

Unlike jurisdictions where synthetic drugs and herbal remedies fall under a single unified licence, Hong Kong separates Western pharmaceutical products and poisons from Chinese herbal medicines and proprietary Chinese medicines across two distinct statutes and two licensing boards. Before preparing an application, a Hong Kong company must classify its products by active ingredients (chemical/biological vs. purely traditional Chinese medicinal materials) to determine the exact statutory licence^[1][3]:

2. Western Pharmaceutical Licences under Cap. 138: ASP Pharmacy vs. LSP Medicine Shop & Wholesale Dealer Licence (WDL)

Under the Pharmacy and Poisons Ordinance (Cap. 138) and the Pharmacy and Poisons Regulations (Cap. 138A), Western medicines in Hong Kong are classified according to toxicity and clinical risk into Part I Poisons (including Prescription-Only Medicines / POM and Pharmacy-Only / Supervised medicines), Part II Poisons (common milder over-the-counter remedies), and Non-Poison Pharmaceutical Products (such as basic vitamins and antiseptic solutions)^[1][2]:

2.1 Retail Comparison: Authorized Seller of Poisons (ASP Pharmacy) vs. Listed Seller of Poisons (LSP Medicine Shop)

Under Section 13B of Cap. 138, the titles "Pharmacy", "Dispensary", Chinese terms for "Pharmacy (藥房)", and the official red-cross "Rx" logo are strictly protected statutory designations. Operating a retail shop using the title "Pharmacy" without an active ASP registration is a criminal offence.

2.2 B2B Distribution & Cross-Border Trade: Wholesale Dealer Licence (WDL · Suffix /2A/)

For Hong Kong corporate applicants that do not operate retail street shops and instead engage in international pharmaceutical trading, supplying Hong Kong Hospital Authority (HA) hospitals, private clinics, and retail pharmacies, or regional APAC distribution, the primary statutory credential is the Wholesale Dealer Licence (WDL, formatted as XX/2A/YYYY, with 1,151 active licensees)^[2]:

• Unified Wholesale + Import/Export Authority: Pursuant to Regulation 26 of Cap. 138A, a WDL authorizes the holder to sell or supply by way of wholesale Part I Poisons, Part II Poisons, and Non-Poison pharmaceutical products, and automatically covers the import and export of pharmaceutical products (eliminating the need for a separate /7A/ Importer/Exporter registration, which only covers non-poisons).
• Strict Prohibition Against Retail Sales (Authorized Buyers Only): A WDL holder is strictly forbidden from selling medicines directly to individual consumers (B2C). Every wholesale transaction must be restricted to legally authorized buyers: Hong Kong registered medical practitioners, registered dentists, registered veterinary surgeons, public/private hospitals, other licensed Wholesale Dealers (WDL), ASP Pharmacies, LSP Medicine Shops (for Part II Poisons and Non-Poisons only), or legitimate overseas medical/pharmaceutical entities.
• Two High-Frequency Add-On Permits (Antibiotics + Dangerous Drugs):
  1. Antibiotics Permit (Cap. 137 Antibiotics Ordinance): Required alongside a WDL if your wholesale product portfolio includes penicillins, cephalosporins, macrolides, or other antimicrobial substances scheduled under Cap. 137;
  2. Dangerous Drugs Wholesale Dealer Licence (Cap. 134 Dangerous Drugs Ordinance): Required if dealing in psychotropic substances, narcotic analgesics, or controlled substances under Cap. 134, mandating a police-inspected reinforced steel Strong Room or High-Security Safe.

3. Chinese Medicine Trader Licences under Cap. 549: Herbal Medicines (Chm) vs. Proprietary Chinese Medicines (pCm)

Corporations trading in raw Chinese herbal slices, ginseng, deer antler, cordyceps, or finished proprietary Chinese medicines (such as pills, medicated oils, syrups, and granules) are regulated under the Chinese Medicine Ordinance (Cap. 549) and the Chinese Medicines Regulation (Cap. 549F) by the Chinese Medicines Board (CMRO) (totaling 8,260 licensed records across Hong Kong)^[3]:

3.1 Statutory Distinction: "Chinese Herbal Medicines (Chm)" vs. "Proprietary Chinese Medicines (pCm)"

• 1. Chinese Herbal Medicines (Chm): Divided under Schedules 1 and 2 of Cap. 549 into two risk tiers:
  • Schedule 1 Chinese Herbal Medicines (31 Potent / Toxic Herbs): Includes raw Aconite root, Cinnabar, Realgar, Strychnos seed, and Arsenic trioxide. Retail dispensing requires a valid prescription signed by a Registered or Listed Chinese Medicine Practitioner (CMP), locked cabinet storage, and strict dispensing register entries;
  • Schedule 2 Chinese Herbal Medicines (574 Common Herbs): Includes Ginseng, American Ginseng, Astragalus, Angelica, Cordyceps, Dendrobium, and Notoginseng.
• 2. Proprietary Chinese Medicines (pCm): Defined under Section 2 of Cap. 549 as any proprietary product composed solely of Chinese herbal medicines as active ingredients, formulated into a finished dosage form (tablets, capsules, pills, medicated oils, plasters, oral liquids), and sold with therapeutic or health claims. Every pCm manufactured, imported, wholesaled, or retailed in Hong Kong must carry an official CMRO registration number (HKC-XXXXX or transitional HKP-XXXXX) printed on its outer package.

3.2 Four Statutory CMRO Trader Licences & the "1 Nominated Supervisor + Up to 2 Deputies" Rule

Pursuant to Sections 114, 115, 131, and 135 of the Chinese Medicine Ordinance (Cap. 549), the Chinese Medicines Board (CMRO) structures its licensing regime across four distinct trader categories based on product class (Chm vs. pCm) and supply-chain tier, while enforcing a strict statutory personnel governance model — "1 Nominated Supervisor + Up to 2 Deputies" — for herbal dispensing and pCm manufacturing^[3]:

4. The Four Hard Prerequisites for Hong Kong Companies: Corporate BRC, GDP Warehouse Zoning, Qualified Personnel & Recall SOPs

Both the Department of Health (Drug Office) and the Chinese Medicines Board (CMRO) enforce a strict sequence: Premises Fit-Out & Equipment Calibration $\rightarrow$ On-Site Inspector Verification $\rightarrow$ Licensing Committee Approval. Based on HC Business Limited's (Licensed TCSP: TC006431) compliance practice, applicants must satisfy four hard requirements^[2][4]:

4.1 Corporate & Branch Business Registration Certificate (Branch BRC) Alignment

• 1. Active Hong Kong Corporation (Cap. 622): The applicant company must maintain "Live" status on the Companies Registry (supported by Certificate of Incorporation CI, latest Annual Return Form NAR1 or Incorporation Form Form NNC1, and Articles of Association);
• 2. Mandatory Branch BRC for Separate Warehouses (Common Rejection Cause): Many pharmaceutical traders lease an administrative office in Central or Tsim Sha Tsui while operating a climate-controlled warehouse in an industrial building in Kwai Chung, Tsuen Wan, or Kwun Tong. Under the Business Registration Ordinance (Cap. 310), every physical warehouse address must obtain a separate Branch Business Registration Certificate (Branch BRC, suffix -001 / -002) via IRD Form IRC 3111A prior to submitting the licence application!

4.2 Physical Premises & Good Distribution Practice (GDP) Climate-Controlled Warehouse Standards

To meet the Department of Health's on-site inspection standards under the Code of Practice for Holder of Wholesale Dealer Licence (GDP Guidelines), your warehouse must implement five physical controls:

1. Four-Zone Color-Coded Physical Segregation:
   • Quarantine Area (Yellow Signage): For newly arrived stock awaiting batch number and packaging verification;
   • Released / Saleable Stock Area (Green Signage): For approved inventory stored on pallets/racks elevated at least 10 cm off the floor and away from walls;
   • Rejected / Returned / Expired Goods Area (Red Locked Cage/Cabinet): Must be physically locked to prevent accidental dispatch of damaged, expired, or customer-returned medicines;
   • Product Recall Quarantine Area: Dedicated locked space for batches subject to statutory recalls.
2. 24-Hour Climate Control & Calibrated Data Loggers:
   • Ambient drug storage zones must run 24-hour continuous air-conditioning and dehumidifiers maintaining room temperature strictly between 15°C and 25°C and relative humidity ≤ 65% RH;
   • Equipped with electronic Temperature & Humidity Data Loggers holding valid HOKLAS or internationally traceable Calibration Certificates, configured with high/low temperature alerts and backed by at least 14–30 days of continuous log charts prior to the inspector's visit;
   • If handling vaccines, insulin, biologics, or cold-chain products, a validated 2°C to 8°C pharmaceutical refrigerator with UPS battery backup, temperature alarm, and validated cold boxes is mandatory.
3. Locked Part I Poison Cupboard: WDL and ASP applicants handling Part I Poisons must install a sturdy, wall- or floor-anchored steel cabinet with a secure lock clearly labelled "Part I Poisons", with keys restricted to the Person-in-Charge or Registered Pharmacist.
4. Pest Control, Lighting & Window Blinds: Insect-proof curtains or UV fly traps, rodent guards, leak-free ceilings, and blackout blinds blocking direct sunlight.
5. Approved Third-Party GDP Logistics Warehouse (3PL Outsourcing Option): Startups that prefer not to build an in-house industrial warehouse may lease an independent commercial office for administration and record-keeping while outsourcing physical drug storage to an existing DH-licensed 3PL GDP warehouse in Hong Kong (such as DKSH Hong Kong Limited) by submitting a signed Technical/Quality Agreement and the 3PL provider's WDL copy.

5. 6-Step Application Workflow, Statutory Fee Schedule & On-Site Inspector Interview Question Bank

Applications for Western drug licences are filed via the Department of Health's online Pharmaceutical Registration and Import/Export Control System (PRLS 2.0 at www.drugoffice.gov.hk), while Chinese medicine trader applications are submitted to the Chinese Medicines Board (CMRO) at 16/F, AIA Kowloon Tower, Landmark East, 100 How Ming Street, Kwun Tong^[2][3].

5.1 6-Step Licensing Roadmap (End-to-End Timeline: ~2.5 to 4 Months)

• Step 1 (Weeks 1–2): Corporate Setup, Stamped Lease & Warehouse Branch BRC — Verify "Live" status on the Companies Registry, execute and stamp the commercial office and industrial warehouse tenancy agreements, and obtain the warehouse Branch BRC from the Inland Revenue Department.
• Step 2 (Weeks 3–5): Warehouse GDP Fit-Out, Scale Floor Plan & 14-Day Temperature Logging — Prepare scaled architectural Floor Plans marking exact dimensions, AC/dehumidifier units, data logger positions, 4-color storage zones, and the locked Part I Poison Cupboard; install calibrated data loggers and accumulate at least 14 consecutive days of temperature/humidity logs.
• Step 3 (Week 6): Formal Submission via DH PRLS 2.0 or CMRO — Submit the application form along with Certified True Copies of CI, Head Office & Branch BRCs, Form NAR1 / Form NNC1, Board Resolution appointing the Person-in-Charge / Nominated Supervisor, stamped tenancy agreement, utility bills, scaled floor plans, and the 8-part GDP SOP Manual.
• Step 4 (Weeks 8–11): Pre-Licensing On-Site Inspection & Closed-Door Competence Interview — Pharmacist Inspectors or CMRO officers inspect the premises, verify calibration certificates and temperature excursion protocols, test the Poison Cupboard lock, and conduct a 45–60 minute oral examination of the Person-in-Charge / Registered Pharmacist / Nominated Supervisor.
• Step 5 (Weeks 12–14): Licensing Committee Approval & Statutory Fee Payment — Upon passing inspection, the file is endorsed by the Licensing Committee and an official Demand Note is issued.
• Step 6 (Weeks 15–16): Licence Issuance, Mandatory Display & Public Register Entry — Display the original licence certificate prominently at the registered premises; the corporation is published on the official DH Drug Office or CMRO public register (and indexed on 86hc.com).

5.2 Official Statutory Fee Schedule (Cap. 138A Schedule 9 & Cap. 549E Schedule)

5.3 Top 5 On-Site Inspector Assessment Scenarios & Compliance Reference Responses

1. Inspector Question 1: "If your warehouse data logger triggers an alarm at 3:00 PM showing the ambient temperature has spiked to 28.5°C, what is your immediate protocol?"

   Model Answer: "First, activate backup air-conditioning immediately and keep warehouse doors closed to prevent warm humid air ingress. Second, place all affected stock under Quarantine (Yellow status) and halt dispatches. Third, export the Temperature Excursion Report from the calibrated data logger and submit it with stability data to the manufacturer's QA department for written disposition assessment. Stock is only released if cleared in writing by QA; otherwise it is moved to the locked Red Rejected Cage for disposal, with a full CAPA report logged."

2. Inspector Question 2: "A buyer claiming to represent a private clinic in Tsim Sha Tsui walks into your office with cash to buy 50 boxes of a Part I Poison prescription drug. Can you hand over the goods?"

   Model Answer: "Strictly no! Before supplying any Part I Poison, we must verify the buyer's active Medical Council registration or ASP/WDL licence on the official register, obtain a written Signed Order bearing the authorized signature/chop of the registered doctor or licensed entity, deliver the goods strictly to their registered practice address, and record the transaction in our Poisons Wholesale Register within 72 hours (retaining records for at least 2 years)."

3. Inspector Question 3: "If the Department of Health orders an urgent Class 1 Recall at 6:00 PM for a batch you distributed to 30 pharmacies last month, how quickly must you act?"

   Model Answer: "For a life-threatening Class 1 Recall, our 24/7 emergency contact activates our Recall SOP immediately (within 24 hours): (1) freeze and lock all remaining warehouse stock of that Batch No. in the Recall Quarantine Area; (2) generate the full downstream distribution list from our batch traceability system within 2 hours; (3) notify all 30 pharmacies via phone, email, and fax to cease dispensing and return stock; and (4) submit periodic Reconciliation Reports to the Drug Office until final destruction."

4. Inspector Question 4: "A pharmacy returns 5 unopened boxes of tablets ordered by mistake. Can your warehouse clerk put them directly back onto the Green Saleable rack?"

   Model Answer: "Never directly! Once medicines leave our climate-controlled custody, they must first be placed in the locked Returned/Quarantine area. They can only return to saleable stock if the buyer provides verifiable continuous temperature logs proving storage within 15°C–25°C, the packaging is intact, and our Person-in-Charge signs a written release inspection. Without verifiable temperature proof, returned medicines must be transferred to the locked Red Rejected Cage for destruction."

5. Inspector Question 5 (CMRO): "If your Nominated Supervisor is on annual leave or resigns, can your shop continue dispensing Schedule 1 toxic Chinese herbs?"

   Model Answer: "Under the Chinese Medicines Regulation (Cap. 549F), when the Nominated Supervisor is temporarily absent, a formally registered Deputy Supervisor (up to 2 may be appointed) must be present on-site to supervise Schedule 1 dispensing. If neither the Nominated Supervisor nor a registered Deputy is present, the Schedule 1 cabinet must remain locked. If the Nominated Supervisor resigns, the licensee must notify CMRO in writing within 1 month to register a qualified replacement."

6. Product Registration (HK-XXXXX / HKC-XXXXX), Cap. 60 Batch Import/Export Licences & Cap. 231 Advertising Red Lines

Securing a corporate dealer licence (WDL or PW-) is only the first layer. Pharmaceutical operations in Hong Kong require compliance across four distinct regulatory gates: Entity Licence + Product Registration + Consignment Import/Export Licence + Medical Advertising Law^[1][5]:

• 1. Western Drug Registration (HK-XXXXX) & the "1+" New Drug Mechanism: Under Regulation 36 of Cap. 138A, every pharmaceutical product sold or distributed in Hong Kong must hold an individual Certificate of Drug Registration (HK- followed by 5 digits) printed on its retail packaging. Under Hong Kong's "1+" Mechanism, innovative New Chemical Entities (NCEs) treating life-threatening or rare diseases can apply for expedited registration in Hong Kong with approval from just 1 reference regulatory authority (out of 36 recognized authorities including the US FDA, EU EMA, UK MHRA, China NMPA, and Japan PMDA) plus local clinical data or expert evaluation.
• 2. Proprietary Chinese Medicine Registration (HKC-XXXXX / HKP-XXXXX): Under Section 119 of Cap. 549, every pCm must pass heavy metal (arsenic, lead, mercury, cadmium), pesticide residue, microbiological limit, and stability testing to obtain an official HKC-XXXXX registration number.
• 3. Mandatory Consignment-Specific Import & Export Licences (Cap. 60): Under the Import and Export Ordinance (Cap. 60), licensed wholesalers must apply via the Hong Kong Trade Single Window (www.tradesinglewindow.hk) for a batch-specific Import Licence or Export Licence prior to every single shipment of pharmaceutical products or proprietary Chinese medicines entering, leaving, or transhipping through Hong Kong. Unlicensed import/export carries a maximum penalty of HK$ 500,000 fine and 2 years' imprisonment.
• 4. Undesirable Medical Advertisements Ordinance (Cap. 231): Schedules 1 and 4 of Cap. 231 strictly prohibit any advertisement (including e-commerce listings, social media posts, and product leaflets) from claiming prevention, treatment, or cure for six restricted disease categories, including cancer/tumours, diabetes, hypertension, cardiovascular disease, epilepsy, kidney disease, and sexual dysfunction.

7. Benchmark Hong Kong Licensed Pharmaceutical Corporations, M&A Due Diligence & 5 High-Risk Anomalies

To illustrate how Department of Health (Cap. 138) and CMRO (Cap. 549) licence numbers map to statutory Companies Registry (CR) filings, our compliance team extracted 8 benchmark licensed pharmaceutical corporations from 86hc.com's 14,061 official regulatory records (click any corporation to inspect its live 86hc profile and official Form NAR1 filings):

7.1 5-Step M&A Due Diligence SOP Before Acquiring an Existing Licensed Pharmacy or Wholesaler

1. Step 1 (Screen for "Dissolved on CR but Still Listed as Licensed" Anomalies): 86hc.com's cross-registry telemetry currently flags 5 high-risk anomalies (DISSOLVED_STILL_LICENSED — 2 ASP pharmacies and 3 CMRO traders) where the corporate entity has already been dissolved at the Companies Registry, extinguishing its legal personality even though its licence number has not yet been purged from the regulator's bulletin. Always verify "Live" corporate status on 86hc DH Register and CMRO Register.
2. Step 2 (Verify the "Premises-Bound" Rule): Both DH licences (ASP / LSP / WDL) and CMRO licences are strictly bound to the approved physical premises. Acquiring 100% of a company's shares without retaining its inspected warehouse lease requires filing a fresh change-of-address application and passing a new on-site inspection.
3. Step 3 (Retrieve Official Barcoded Forms NAR1, ND2A & NM1): Inspect the target's latest Annual Return (Form NAR1), Notice of Change of Director (Form ND2A), and Mortgage/Charge Filings (Form NM1) to verify shareholding title and ensure drug registrations are not pledged to lenders.
4. Step 4 (Audit DH Convictions & PPBHK Disciplinary Records): Check whether the pharmacy or wholesaler has pending summonses for illegal sale of Part I Poisons without a pharmacist or sale of unregistered drugs, which can trigger licence revocation post-closing.
5. Step 5 (Screen High Court Civil Writs & Winding-Up Petitions): Run a 7-Tier Court Litigation & Winding-Up Search to rule out unpaid supplier claims (HCA / DCCJ) or compulsory winding-up petitions (HCCW).

8. Corporate Bank Account Opening (HSBC HK & OCBC HK) KYB Pre-Screening & Practising CPA CTC Certification

Commercial banks in Hong Kong — including HSBC Hong Kong and OCBC Bank Hong Kong — apply Enhanced Due Diligence (EDD) to corporate applicants whose names or business nature involve pharmaceuticals, medicines, pharmacies, or biotechnology:

• 1. "Pre-Licence Corporate Account Opening" for New Pharma Entities: Because leasing a Hong Kong warehouse and paying contractors requires a local corporate bank account before the WDL/CMRO licence is formally issued, newly incorporated pharma companies can apply for a corporate bank account during the licence preparation stage by presenting: (i) Stamped Hong Kong warehouse lease & Branch BRC, (ii) DH PRLS or CMRO application acknowledgement receipt, (iii) Directors' or parent group's pharmaceutical GSP/GMP credentials, and (iv) Letters of intent with licensed suppliers/buyers to facilitate bank KYB review (Note: Pursuant to the Hong Kong Banking Ordinance, Cap. 155, licensed commercial banks retain sole final discretion over account approval).
• 2. Controlled Precursor & Sanctions Compliance Declaration: Explicitly declare in your KYB business plan that the company does not trade in controlled precursor chemicals (such as ephedrine or fentanyl precursors under Cap. 145) or transact with sanctioned jurisdictions.
• 3. Practising CPA Certified True Copies (CTC) & Hague Apostille: When bidding for Hospital Authority (HA) tenders, executing multinational distributorships, or filing cross-border drug registrations, engage a Hong Kong Practising CPA regulated by the AFRC to issue Certified True Copies (CTC) of your CI, BRC, Form NAR1, and DH/CMRO licences.

9. Frequently Asked Questions (FAQs) on Hong Kong Pharmaceutical Licensing